ArticleThe Journal of clinical investigation2001

IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy.

J M Wigginton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.